Merlin and ERM proteins: unappreciated roles in cancer development?
McClatchey
Andrea I
AI
Massachusetts General Hospital Cancer Center, Harvard Medical School Department of Pathology, 149 13th Street, Charlestown, Massachusetts 02129, USA. mcclatch@helix.mgh.harvard.edu
D001798:Blood Proteins / Q000494:pharmacology*; D002462:Cell Membrane / Q000648:ultrastructure; D002471:Cell Transformation, Neoplastic; D003598:Cytoskeletal Proteins / Q000494:pharmacology*; D006801:Humans; D008565:Membrane Proteins / Q000494:pharmacology*; D008840:Microfilament Proteins / Q000494:pharmacology*; D009369:Neoplasms / Q000503:physiopathology; D025581:Neurofibromin 2 / Q000494:pharmacology*; D010750:Phosphoproteins / Q000494:pharmacology*; D015398:Signal Transduction; D020741:rho GTP-Binding Proteins / Q000494:pharmacology; D000099149:Ezrin
D001798:Blood Proteins; D003598:Cytoskeletal Proteins; D008565:Membrane Proteins; D008840:Microfilament Proteins; D025581:Neurofibromin 2; D010750:Phosphoproteins; D020741:rho GTP-Binding Proteins; D000099149:Ezrin; C071058:moesin; C071776:radixin